Esketamine monotherapy is linked to greater 28-day symptom reduction in treatment-resistant depression vs placebo, new research shows.

Data from three terminally ill cardiogenic shock patients showcase potential of procizumab to safely reverse shock within 48 hours and provide promising first-in-human evidence on the translatability ...

If you have $1,000 to invest right now, you may be wondering where to get started. You could buy stocks that are flying high ...

AstraZeneca’s drug candidate baxdrostat lowered systolic blood pressure in a phase 3 clinical trial involving patients with uncontrolled or treatment-resistant hypertension. In the trial, patients who ...

Scientists have discovered that a locally developed cancer drug, PRL3-zumab, may offer a groundbreaking treatment for two ...

Daré Bioscience shares rallied after the biopharmaceutical company released positive interim safety and efficacy results from the Phase 3 clinical trial of its contraceptive drug. Shares climbed 86% ...

Karen Peterson was diagnosed with stage 1 triple-negative breast cancer that quickly returned as stage 4. Joining a clinical ...

AnaptysBio’s lead drug rosnilimab showed promise in RA, but lack of a Phase 3 plan and limited pipeline raise concerns. Find ...

Ophthalmology Times connects eye care professionals with surgery, imaging, gene therapy, & diagnostic advances to enhance ...

Merck (NYSE: MRK), known as MSD outside of the United States and Canada, today announced the initiation of the EXPrESSIVE Phase 3 clinical trials, evaluating the safety and efficacy of MK-8527, an ...

Sotatercept-csrk was first approved in 2024 to treat pulmonary arterial hypertension (PAH) in adults based on results seen in the phase 3 STELLAR trial.

The goal with ProKidney Corp.'s rilparencel-branded therapy is "to demonstrate the therapy's potential to preserve kidney ...